Treatment

Medicines may treat selected symptoms or stroke risk, but they do not reopen the arteries narrowed by moyamoya. Revascularization can create additional routes for blood flow, and the decision depends on symptoms, imaging, hemodynamics, age, and overall health.

Treatment selection integrates ischemic or hemorrhagic presentation, symptomatic territory, silent injury, cerebrovascular reserve, donor and recipient anatomy, perioperative risk, and the limits of mostly observational evidence.

Clinical updates

Guideline patch notes

2023 AHA statement

American Heart Association and American Stroke Association

Describes adult presentation, diagnostic assessment, medical care, and individualized revascularization decisions.

Read registered source

2023 ESO guideline

European Stroke Organisation

Emphasizes experienced referral centers and consensus-based selection of direct, indirect, or combined strategies.

Read registered source

2021 Japanese guideline

Research Committee on Moyamoya Disease and Japan Stroke Society

Addresses surgery for ischemic and selected hemorrhagic presentations together with perioperative management.

Read registered source

Revascularization

Revascularization surgery is the main treatment that can provide additional routes for blood to reach threatened brain tissue. Options include direct bypass, indirect revascularization, or a combined operation. Japanese guidance recommends surgical revascularization for appropriate ischemic presentations and supports consideration in selected hemorrhagic disease. [1]

Surgery is not a one-size-fits-all rule. Teams consider whether symptoms match the affected territory, whether imaging shows impaired hemodynamics, whether silent injury is accumulating, and whether donor and recipient vessels support a particular technique. European expert consensus favors experienced referral centers and generally favors direct or combined approaches over indirect-only surgery for many adults, while pediatric strategy often relies heavily on indirect techniques. [2]

Medical management

Medicines do not reverse the underlying arterial narrowing. Antiplatelet therapy may be considered in selected nonhemorrhagic patients, but the evidence is limited and bleeding risk, prior events, surgery timing, and other conditions matter. Blood pressure, hydration, fever, anemia, pain, and ventilation can affect cerebral blood flow; management targets are individualized.

Symptoms such as seizures, headache, and vascular risk factors are treated according to their own indications. People should not start, stop, or change aspirin, anticoagulants, blood-pressure medicines, or migraine treatments solely from general web information.

Team-based decisions

Care may involve vascular neurology, cerebrovascular neurosurgery, neuroradiology, anesthesiology, rehabilitation, genetics, pediatrics, and other specialties. A useful consultation explains what problem treatment is intended to solve, alternatives, expected timing of benefit, perioperative risks, and the follow-up plan. [3]

Clinical detail

The strength of evidence differs by presentation and age. Randomized data are limited, and many recommendations combine observational studies with expert consensus. Treatment discussions should distinguish evidence-based recommendations from local practice preferences.